NovAliX and Servier Collaborate in Early Discovery Research Program
News Oct 10, 2012
NovAliX has announced that it has entered into drug discovery collaboration with the pharmaceutical company Servier.
NovAliX will identify hits using its Graffinity fragment-based screening technology that combines chemical micro-arrays with a proprietary SPR-imaging method for the detection of compound protein interactions.
NovAliX will receive technology access fees and research funding from Servier.
"We look forward to utilizing NovAliX's strong capabilities in biophysics and lead generation methodologies for this novel discovery program" said Bernard Marchand, PhD, Head of Servier Discovery Research.
Stephan Jenn, President of NovAliX, said "This drug discovery collaboration with a leading global pharmaceutical confirms the quality of our technologies and science, and underlines the value of our platform as an important tool to deliver valuable lead candidates."
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE